• J Rynne, M Mosavie, Marie-Hélène Masse, Julie Ménard, Marie-Claude Battista, David M Maslove, Lorenzo Del Sorbo, Charles St-Arnaud, Frederick DAragon, Alison Fox-Robichaud, Emmanuel Charbonney, AdhikariNeill K JNKJDepartment of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada. neill.adhikari@utoronto.ca.Interdepartmental Division of Critical Care Medicine and Institute for Health Policy, Management, and Evaluation, Univ, François Lamontagne, M Shankar-Hari, and LOVIT Investigators, the Canadian Critical Care Trials Group.
• Centre for Inflammation Research, Institute For Regeneration and Repair, University of Edinburgh, Edinburgh, Scotland, UK.
• Intensive Care Med. 2025 Jan 7.

PurposeWe hypothesised that the biological heterogeneity of sepsis may highlight sepsis subtypes with differences in response to intravenous vitamin C treatment in the Lessening Organ Dysfunction with VITamin C (LOVIT) trial. Our aims were to identify sepsis subtypes and to test whether sepsis subtypes have differences in treatment effect to vitamin C and describe putative biological effects of vitamin C treatment.MethodsWe measured biomarkers of inflammation, at baseline and at 7 days post-randomisation, in 457/863 (53.0%) of participants with plasma samples in the LOVIT trial. We used agglomerative hierarchical clustering on log10-transformed baseline data of 26 biomarkers to identify sepsis subtypes. We analysed differences in vitamin C treatment effect with regression models incorporating robust standard errors to report odds ratio and 95% confidence intervals (OR(95% CI)). All analyses were completed blinded to treatment allocation.ResultsOur cohort included 233/429 (54.3%) allocated to vitamin C and 224/434 (51.6%) allocated to placebo. A three-subtype model best explained the variance in our data. Subtype-2 had the highest, and subtype-3 had the lowest levels of inflammatory response. In paired longitudinal samples, vitamin C did not have discernible anti-inflammatory effects, with anti-inflammatory effects related to time since randomisation and concomitant hydrocortisone treatment. The treatment effect estimates (OR (95% CI)) for subtype-1, subtype-2 and subtype-3 were 1.04 (0.63-1.73), 1.33 (0.53-3.36) and 1.95 (0.85-4.49), respectively (test of heterogeneity p = 0.002).ConclusionWe report three sepsis subtypes based on inflammatory response profile. No subtype benefitted from vitamin C treatment in the LOVIT trial, with heterogeneity of treatment effect in the magnitude of harm.Trial RegistrationFunded by the Lotte and John Hecht Memorial Foundation; LOVIT ClinicalTrials.gov number, NCT03680274.© 2025. Springer-Verlag GmbH Germany, part of Springer Nature.

7 keywords...

hide…